Back to top
more

ABIOMED, Inc. (ABMD)

(Delayed Data from NSDQ)

$271.75 USD

271.75
1,074,902

+6.98 (2.64%)

Updated May 3, 2019 04:00 PM ET

After-Market: $271.72 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Abiomed (ABMD) Could Beat Earnings Estimates Again

by Zacks Equity Research

Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

by Zacks Equity Research

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips

by Zacks Equity Research

Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Abiomed (ABMD) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval

by Zacks Equity Research

Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.

Abiomed (ABMD) Posts Impellas Positive Study Results in Japan

by Zacks Equity Research

Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.

Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.

3 Reasons to Hold Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Implied Volatility Surging for Abiomed (ABMD) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Abiomed (ABMD) stock based on the movements in the options market lately.

Abiomed's (ABMD) Impella Favored by Latest Study Result

by Zacks Equity Research

Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.

Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

Abiomed (ABMD) Q1 Earnings Top Estimates

by Zacks Equity Research

Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Device Stocks Earnings on Aug 4: BDX, ABMD, AMN & DOCS

by Debanjana Dey

The Medical Device companies' Q2 results are likely to reflect strength in customer demand. Let's see how BDX, ABMD, AMN and DOCS are placed ahead of their earnings releases.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q1 sales.

    How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

    by Zacks Equity Research

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

    Abiomed (ABMD) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Abiomed (ABMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Can Abiomed (ABMD) Keep the Earnings Surprise Streak Alive?

    by Zacks Equity Research

    Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

    by Zacks Equity Research

    Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

    Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

    by Zacks Equity Research

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

    Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

    by Zacks Equity Research

    Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.